Tag: Hcv

Over 90% of chronic hepatitis C (HCV) cases can now be cured with well-tolerated, oral direct-acting antiviral (DAA) medications. The landmark drug Harvoni (ledipasvir/sofosbuvir) revolutionized this treatment landscape upon its 2014 approval, offering a highly effective, interferon-free regimen for specific genotypes. Although newer pan-genotypic therapies have emerged, Harvoni is still used for certain patient profiles and indications.

According to clinical data, Zepatier demonstrates cure rates of over 95% for eligible patients with HCV genotypes 1 or 4. The question of how long does it take for Zepatier to work involves understanding the difference between when the medication starts fighting the virus and when a patient is officially considered cured.

Globally, an estimated 50 million people have chronic hepatitis C virus (HCV) infection. The answer to 'What is the new cure for hep C?' lies in direct-acting antiviral (DAA) medications, which can cure more than 95% of cases.

In 2023, there were an estimated 69,000 new acute Hepatitis C virus (HCV) infections in the United States. Direct-acting antivirals are key to treatment, and understanding **how does Zepatier work** reveals a powerful dual mechanism that halts viral replication, offering a cure for many.